DALLAS / Aug 10, 2023 / Business Wire / Tenet Healthcare Corporation (NYSE: THC) today announced the appointment of Senator Roy Blunt to the Tenet Board of Directors, effective immediately. Senator Blunt will serve as a member of the Audit Committee, Nominating and Corporate Governance Committee, and Environmental, Social, and Governance Committee. This appointment expands the Board to 12 directors, 11 of whom are independent members.
“We are pleased to welcome Senator Roy Blunt as a new board member,” said Saum Sutaria, M.D., Chief Executive Officer of Tenet. “With more than 25 years of legislative experience, Roy’s expertise in public policy and addressing cross-cutting issues will be invaluable to helping Tenet make a lasting, positive impact on the communities we serve while also increasing long-term value for our shareholders.”
Senator Blunt is currently the Chairman of the Leadership Advisory Strategies group at Husch Blackwell Strategies. Senator Blunt was elected to the U.S. House of Representatives in 1996 and U.S. Senate in 2010, consistently demonstrating his commitment to serving the public with unwavering integrity and purpose. Throughout his career, Senator Blunt has spearheaded major legislative achievements in health care and other highly regulated industries, with a commitment to medical research and discovery.
Senator Blunt served on committees in Congress where his leadership helped shape key policies. This includes service as Chairman of the Senate Rules Committee as well as serving on the Senate Appropriations Committee, Senate Commerce, Science and Transportation Committee, and the Senate Select Committee on Intelligence. Notably, Senator Blunt was Chairman of the Appropriations Subcommittee on Labor, Health and Human Services, and Education, underscoring his focus on health care and health research. During his eight years on the subcommittee, Senator Blunt focused resources and awareness on critical issues including increasing funding for medical research centers and Alzheimer’s disease research.
Prior to his tenure in Congress, he was a history teacher, county official, and Missouri’s Secretary of State. Senator Blunt also served four years as the president of Southwest Baptist University. Senator Blunt is actively involved in promoting and preserving the arts and history. He has served as a member of the Smithsonian Council for American Art, as President of the State Historical Society of Missouri, and as a member of the Kennedy Center Board of Trustees.
Senator Blunt is an Executive Fellow at the Bipartisan Policy Center in Washington, D. C. He also chairs the Advisory Board of the National Geospatial Agency of the U. S. Government and serves on the Southwest Airlines Board of Directors.
About Tenet Healthcare
Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas. Our care delivery network includes United Surgical Partners International, the largest ambulatory platform in the country, which operates or has ownership interests in more than 475 ambulatory surgery centers and surgical hospitals. We also operate 61 acute care and specialty hospitals, approximately 110 other outpatient facilities, a network of leading employed physicians and a global business center in Manila, Philippines. Our Conifer Health Solutions subsidiary provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers, and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit www.tenethealth.com.
Last Trade: | US$153.40 |
Daily Change: | -8.58 -5.30 |
Daily Volume: | 2,205,695 |
Market Cap: | US$14.700B |
July 24, 2024 April 30, 2024 February 08, 2024 December 13, 2023 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB